title: [Non-adherence to biological therapy in patients with rheumatic diseases in the Brazilian Unified National Health System in Minas Gerais State, Brazil].
abstract: This study examined non-adherence to biological therapy with adalimumab and etanercept and associated factors in patients with rheumatic diseases treated under the Brazilian Unified National Health System in Minas Gerais State, Brazil. A non-concurrent cohort study was performed from pharmacy records of adult patients that had recently initiated treatment. Patient non-adherence was measured by proportion of days covered (PDC), and non-adherent patients were defined as PDC < 0.8. A total of 1,150 patients were included, with the following breakdown: 64.3% rheumatoid arthritis, 8.5% psoriatic arthritis , and 27.2% ankylosing spondylitis. In total, 33.5% of patients were non-adherent. Factors such as younger age (19-39 years), female gender, diagnosis of rheumatoid arthritis , and initial treatment with etanercept were associated with low adherence. The results indicate a high prevalence of non-adherence, which can lead to worse health outcomes and increase healthcare use and costs.
authors.affiliation: Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
authors.forename: Clarice Gomes E Souza
authors.initials: CG
authors.lastname: Dabés
authors.affiliation: Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
authors.forename: Alessandra Maciel
authors.initials: AM
authors.lastname: Almeida
authors.affiliation: Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
authors.forename: Francisco de Assis
authors.initials: Fde A
authors.lastname: Acurcio
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001691:Biological Therapy; D015331:Cohort Studies; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012216:Rheumatic Diseases / Q000188:drug therapy*; D016903:Drug Monitoring
chemical_list: D018501:Antirheumatic Agents; D000068879:Adalimumab; D000068800:Etanercept